ClinicalTrials.gg
TerminatedNCT06654245SHAREDCareUpdated Oct 22, 2026Results posted

Assessing and Addressing Follow-up Care Needs That Will Facilitate Care Transitions for Cancer Survivors

An interventional study of Telephone based interview and Survey using a questionnaire. in Stage I Lung Cancer, Stage II Lung Cancer and Stage III Lung Cancer, sponsored by Wake Forest University Health Sciences. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Supportive care

How we know

Why this study was terminated
Low accruals, PI decision
Updated Oct 22, 2026Results postedStudy documents postedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Lung Neoplasms by Wake Forest University Health Sciences — 3 open to participants now, 6 under way, none of them phase 3. Lung Neoplasms · Wake Forest University Health Sciences.

Enrollment
28th of 31
5 · median 46
Started
2025
with 1 other
No phase
14 of 36
3 open now
Registered
34th of 36
by date

Among the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences, this one is the 28th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 with no phase, and was the 34th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

3 of the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Lung Neoplasms by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

This clinical trial evaluates whether a shared response plan (SHAREDCare) improves follow-up care for lung cancer survivors. As the number of cancer survivors increases, there is a new need for high-quality chronic illness care. High-quality chronic illness care can be difficult to deliver and involves working with the patient to be certain they have what they need to be actively involved with their care to meet their needs. SHAREDCare allows the patient to work with a navigator to review identified distress and social needs. The patient and navigator discuss the needs and develop a shared response plan to address the needs in ways that consider the patient's current behaviors, beliefs, and motivation. The plan also establishes specific patient goals, anticipates barriers, and establishes how the navigator will follow-up on the needs and adjust care and assistance when needed. Using a shared response plan may improve follow-up care for lung cancer survivors.

Read the detailed description

Primary Objective: Pilot and qualitatively assess the acceptability of SHAREDCare through semi- structured interviews

Secondary Objectives:

  • Describe quantitative assessments of intervention acceptability, appropriateness, and feasibility.
  • Describe survivor level of unmet needs13 using a validated measure to collect data before and/or after completion of the SHAREDCare intervention.
  • Track clinical referrals and other actions made as a result of patient responses on the Electronic Distress Screening (EDS) and the percentage of referrals that have been "completed" (i.e. those referrals where a patient completed the relevant medical or social needs-related visit).
  • Track recruitment, assessment completion, and any related adverse events.

OUTLINE:

Patients receive a SHAREDCare call with a navigator to discuss identified distress and social needs and develop/deploy a shared response plan to address identified needs on study. Patients also receive standard of care automated referrals on study. Two weeks following the initial call, patients receive a second SHAREDCare call with a navigator to follow-up on the shared response plan.

After completion of study intervention, patients are followed up 4 weeks after initial call.

03

Conditions studied

  • Stage I Lung Cancer
  • Stage II Lung Cancer
  • Stage III Lung Cancer
  • Stage IV Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients must have or cytologically confirmed study disease. A pathology report should be referenced/available (stages I-IV lung cancer)
  • Ability to understand and the willingness to sign an institutional review board (IRB)-approved document
  • ≥ 18 years of age
  • Within two years of lung cancer diagnosis
  • Able to understand, read and write English

Exclusion Criteria: Does not meet the above inclusion criteria

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    SHAREDCare Supportive care arm

    Patients receive a SHAREDCare call with a navigator to discuss identified distress and social needs and develop/deploy a shared response plan to address identified needs on study. Patients also receive standard of care automated referrals on study. Two weeks following the initial call, patients receive a second SHAREDCare call with a navigator to follow-up on the shared response plan.

    Behavioral: Telephone based interview · Other: Survey using a questionnaire. · Other: Electronic health record review · Other: Referral

Interventions

  • BehavioralTelephone based interview

    Receive SHAREDCare navigator calls

  • OtherSurvey using a questionnaire.

    Ancillary studies

  • OtherElectronic health record review

    Ancillary studies

  • OtherReferral

    Receive standard of care automated referrals

06

What researchers measure

Primary outcomes

  1. SHAREDCare's Qualitative Acceptability

    Will be assessed with semi-structured interviews. These methods will be guided by Grounded Theory, a process using inductive coding to develop theory from data (e.g., themes relating to components, timing, or delivery of the intervention).

    Time frame: At 4 weeks post-initial call

Secondary outcomes

  1. SHAREDCare's Quantitative Acceptability

    Measured using the Acceptability of Intervention Measure (AIM), a 4-item instrument assessing perceived acceptability of an intervention. Each item is rated on a 1-5 Likert scale, with higher scores indicating greater acceptability. The overall AIM score is calculated as the mean of the four items and ranges from 1 to 5.

    Time frame: At 4 weeks post-initial call

  2. SHAREDCare's Quantitative Feasibility

    Measured using the Feasibility of Intervention Measure (FIM), a 4-item instrument assessing the perceived feasibility of an intervention. Each item is rated on a 1-5 Likert scale, with higher scores indicating greater feasibility. The overall FIM score is calculated as the mean of the four items and ranges from 1 to 5.

    Time frame: At 4 weeks post-initial call

  3. SHAREDCare's Quantitative Appropriateness

    Measured using the Intervention Appropriateness Measure (IAM), a 4-item instrument assessing perceived appropriateness of an intervention. Each item is rated on a 1-5 Likert scale, with higher scores indicating greater appropriateness. The overall IAM score is calculated as the mean of the four items and ranges from 1 to 5.

    Time frame: At 4 weeks post-initial call

  4. Total Survivor Unmet Needs Survey Score

    Measured using the Survivor Unmet Needs Survey, a 30-item instrument assessing cancer survivors' unmet supportive care needs. Each item is scored from 0 (no unmet need) to 4 (very high unmet need). Item scores are summed to create a total score ranging from 0 to 120, with higher scores indicating greater unmet needs and a worse outcome. Total scores were assessed at baseline and 4 weeks post-initial call

    Time frame: At baseline and at 4 weeks post-initial call

  5. Number of Clinical Referrals Made

    Total number of referrals generated during the SHAREDCare intervention, including referrals to supportive care services such as tobacco cessation, nutrition, health coaching, financial navigation, and palliative care.

    Time frame: At 4 weeks post-initial call

  6. Number of Referrals Completed

    Defined as those referrals where a patient self-reported completing visit through 4 weeks post-initial call.

    Time frame: At 4 weeks post-initial call

  7. Number of Participants Enrolled

    The number of eligible participants enrolled in the study was assessed. Reasons for non-enrollment among eligible participants were recorded and summarized descriptively.

    Time frame: During study recruitment over 5 months

  8. Percentage of Participants With Completion of All Follow-up Visits

    Retention was assessed as the percentage of enrolled participants who completed all planned follow-up assessments through the end of study participation.

    Time frame: Through 4 weeks post-initial call

07

Results

Posted Oct 22, 2026

Participant flow

Participant flow — Overall Study
MilestoneSHAREDCare Supportive Care Arm
Started5
Completed5
Not completed0

Outcome measures

PrimarySHAREDCare's Qualitative Acceptability

Will be assessed with semi-structured interviews. These methods will be guided by Grounded Theory, a process using inductive coding to develop theory from data (e.g., themes relating to components, timing, or delivery of the intervention).

Time frame:
At 4 weeks post-initial call
Reported as:
Count of participants · Participants
SHAREDCare's Qualitative Acceptability
ParticipantsSHAREDCare Supportive Care Arm
SHAREDCare meets approval5
SHAREDCare is appealing5
SHAREDCare is liked5
SHAREDCare is welcomed5
Patients value coordinated support, but role fit, timing, and screening alignment concerns exist5
SecondarySHAREDCare's Quantitative Acceptability

Measured using the Acceptability of Intervention Measure (AIM), a 4-item instrument assessing perceived acceptability of an intervention. Each item is rated on a 1-5 Likert scale, with higher scores indicating greater acceptability. The overall AIM score is calculated as the mean of the four items and ranges from 1 to 5.

Time frame:
At 4 weeks post-initial call
Reported as:
Mean · score on a scale
SHAREDCare's Quantitative Acceptability
score on a scaleSHAREDCare Supportive Care Arm
SHAREDCare's Quantitative Acceptability4.25 ± 0.43
SecondarySHAREDCare's Quantitative Feasibility

Measured using the Feasibility of Intervention Measure (FIM), a 4-item instrument assessing the perceived feasibility of an intervention. Each item is rated on a 1-5 Likert scale, with higher scores indicating greater feasibility. The overall FIM score is calculated as the mean of the four items and ranges from 1 to 5.

Time frame:
At 4 weeks post-initial call
Reported as:
Mean · score on a scale
SHAREDCare's Quantitative Feasibility
score on a scaleSHAREDCare Supportive Care Arm
SHAREDCare's Quantitative Feasibility4.20 ± 0.45
SecondarySHAREDCare's Quantitative Appropriateness

Measured using the Intervention Appropriateness Measure (IAM), a 4-item instrument assessing perceived appropriateness of an intervention. Each item is rated on a 1-5 Likert scale, with higher scores indicating greater appropriateness. The overall IAM score is calculated as the mean of the four items and ranges from 1 to 5.

Time frame:
At 4 weeks post-initial call
Reported as:
Mean · score on a scale
SHAREDCare's Quantitative Appropriateness
score on a scaleSHAREDCare Supportive Care Arm
SHAREDCare's Quantitative Appropriateness4.10 ± 0.55
SecondaryTotal Survivor Unmet Needs Survey Score

Measured using the Survivor Unmet Needs Survey, a 30-item instrument assessing cancer survivors' unmet supportive care needs. Each item is scored from 0 (no unmet need) to 4 (very high unmet need). Item scores are summed to create a total score ranging from 0 to 120, with higher scores indicating greater unmet needs and a worse outcome. Total scores were assessed at baseline and 4 weeks post-initial call

Time frame:
At baseline and at 4 weeks post-initial call
Reported as:
Mean · Scores on a scale
Total Survivor Unmet Needs Survey Score
Scores on a scaleSHAREDCare Supportive Care Arm
Scores on a scale reported at baseline9.6 ± 13.3
Scores on a scale reported at 4-weeks post initial call10.2 ± 13.5
SecondaryNumber of Clinical Referrals Made

Total number of referrals generated during the SHAREDCare intervention, including referrals to supportive care services such as tobacco cessation, nutrition, health coaching, financial navigation, and palliative care.

Time frame:
At 4 weeks post-initial call
Reported as:
Number · Referrals
Number of Clinical Referrals Made
ReferralsSHAREDCare Supportive Care Arm
Number of Clinical Referrals Made7
SecondaryNumber of Referrals Completed

Defined as those referrals where a patient self-reported completing visit through 4 weeks post-initial call.

Time frame:
At 4 weeks post-initial call
Reported as:
Number · Self-reported completed referrals
Number of Referrals Completed
Self-reported completed referralsSHAREDCare Supportive Care Arm
Number of Referrals Completed8
SecondaryNumber of Participants Enrolled

The number of eligible participants enrolled in the study was assessed. Reasons for non-enrollment among eligible participants were recorded and summarized descriptively.

Time frame:
During study recruitment over 5 months
Reported as:
Count of participants · Participants
Number of Participants Enrolled
ParticipantsSHAREDCare Supportive Care Arm
Number of Participants Enrolled5
SecondaryPercentage of Participants With Completion of All Follow-up Visits

Retention was assessed as the percentage of enrolled participants who completed all planned follow-up assessments through the end of study participation.

Time frame:
Through 4 weeks post-initial call
Reported as:
Count of participants · Participants
Percentage of Participants With Completion of All Follow-up Visits
ParticipantsSHAREDCare Supportive Care Arm
Percentage of Participants With Completion of All Follow-up Visits5

Adverse events

Collected over Baseline through 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SHAREDCare Supportive Care Arm0/5 (0%)0/5 (0%)0/5 (0%)

Baseline characteristics

Age, Customized
Age, Customized(Age in Years)SHAREDCare Supportive Care Arm
Mean age in years70.8 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)SHAREDCare Supportive Care Arm
Female4
Male1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SHAREDCare Supportive Care Arm
Hispanic or Latino0
Not Hispanic or Latino5
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SHAREDCare Supportive Care Arm
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White3
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center (AH-WFBCCC)
    Winston-Salem, North Carolina 27157, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Jan 2026, 7 months.

Results were first posted in Oct 2026, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2024
First posted
Oct 23, 2024
StartActual
Jun 11, 2025
Primary completionActual
Jan 12, 2026
CompletionActual
Jan 12, 2026
Results first posted
Oct 22, 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 22, 2026
Documents
Secondary outcomes
2 edited, 2 added, 3 removed, 4 description edited
What changed in the outcomes
  • EditedPercentageNumber of Referrals CompletedTime frame: At 4 weeks post-initial call
  • EditedNumber of Participants Enrolled/EligibleTime frame: At 4 weeks post-initial call → During study recruitment over 5 months
  • AddedTotal Survivor Unmet Needs Survey ScoreTime frame: At baseline and at 4 weeks post-initial call
  • AddedPercentage of Participants With Completion of All Follow-up VisitsTime frame: Through 4 weeks post-initial call
  • RemovedNumber of Survivors With Unmet NeedsTime frame: At baseline and at 4 weeks post-initial call
  • RemovedPercentage of Assessments CompletedTime frame: At 4 weeks post-initial call
  • RemovedNumber of Adverse Events ReportedTime frame: At baseline (initial call) up to 4 weeks post-initial call
  • DescriptionNumber of Clinical Referrals Made: how it is measured was reworded
  • DescriptionSHAREDCare's Quantitative Acceptability: how it is measured was reworded
  • DescriptionSHAREDCare's Quantitative Appropriateness: how it is measured was reworded
  • DescriptionSHAREDCare's Quantitative Feasibility: how it is measured was reworded
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Results posted
    Secondary outcomes 2 edited, 2 added, 3 removed, 4 description edited
    What changed in the outcomes
    • EditedPercentageNumber of Referrals CompletedTime frame: At 4 weeks post-initial call
    • EditedNumber of Participants Enrolled/EligibleTime frame: At 4 weeks post-initial call → During study recruitment over 5 months
    • AddedTotal Survivor Unmet Needs Survey ScoreTime frame: At baseline and at 4 weeks post-initial call
    • AddedPercentage of Participants With Completion of All Follow-up VisitsTime frame: Through 4 weeks post-initial call
    • RemovedNumber of Survivors With Unmet NeedsTime frame: At baseline and at 4 weeks post-initial call
    • RemovedPercentage of Assessments CompletedTime frame: At 4 weeks post-initial call
    • RemovedNumber of Adverse Events ReportedTime frame: At baseline (initial call) up to 4 weeks post-initial call
    • DescriptionNumber of Clinical Referrals Made: how it is measured was reworded
    • DescriptionSHAREDCare's Quantitative Acceptability: how it is measured was reworded
    • DescriptionSHAREDCare's Quantitative Appropriateness: how it is measured was reworded
    • DescriptionSHAREDCare's Quantitative Feasibility: how it is measured was reworded
    + 4 other changes: index terms, verification date, contact details and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06654245
Responsible party
Sponsor
First posted
Oct 23, 2024
Start date
Jun 11, 2025
Primary completion
Jan 12, 2026
Completion
Jan 12, 2026
Results posted
Oct 22, 2026
Last update
Oct 22, 2026

Study contacts

Sarah Birken, PhD
principal investigator · Wake Forest University Health Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion